- Home
- ZENV vs NVNO Comparison
ZENV vs NVNO Comparison
Compare ZENV & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- NVNO
- Stock Information
- Founded
- ZENV 2005
- NVNO 1987
- Country
- ZENV Brazil
- NVNO United States
- Employees
- ZENV N/A
- NVNO N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- NVNO Medical/Dental Instruments
- Sector
- ZENV Technology
- NVNO Health Care
- Exchange
- ZENV Nasdaq
- NVNO Nasdaq
- Market Cap
- ZENV 79.7M
- NVNO 16.7M
- IPO Year
- ZENV 2021
- NVNO N/A
- Fundamental
- Price
- ZENV $1.16
- NVNO $0.91
- Analyst Decision
- ZENV
- NVNO
- Analyst Count
- ZENV 0
- NVNO 0
- Target Price
- ZENV N/A
- NVNO N/A
- AVG Volume (30 Days)
- ZENV 91.4K
- NVNO 2.4M
- Earning Date
- ZENV 09-10-2025
- NVNO 10-30-2025
- Dividend Yield
- ZENV N/A
- NVNO N/A
- EPS Growth
- ZENV N/A
- NVNO N/A
- EPS
- ZENV N/A
- NVNO N/A
- Revenue
- ZENV $201,426,369.00
- NVNO N/A
- Revenue This Year
- ZENV $6.49
- NVNO N/A
- Revenue Next Year
- ZENV $3.82
- NVNO N/A
- P/E Ratio
- ZENV N/A
- NVNO N/A
- Revenue Growth
- ZENV 24.80
- NVNO N/A
- 52 Week Low
- ZENV $1.02
- NVNO $0.67
- 52 Week High
- ZENV $3.03
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- ZENV 33.18
- NVNO 25.20
- Support Level
- ZENV $1.23
- NVNO $0.67
- Resistance Level
- ZENV $1.85
- NVNO $0.93
- Average True Range (ATR)
- ZENV 0.11
- NVNO 0.07
- MACD
- ZENV -0.05
- NVNO 0.13
- Stochastic Oscillator
- ZENV 4.15
- NVNO 86.70
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.